TherapeuticsMD Inc (TXMD) Insider Sells $1,525,000.00 in Stock

TherapeuticsMD Inc (NASDAQ:TXMD) insider John C.K. Iv Milligan sold 250,000 shares of TherapeuticsMD stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $6.10, for a total value of $1,525,000.00. Following the completion of the transaction, the insider now owns 1,597,419 shares in the company, valued at $9,744,255.90. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of TherapeuticsMD stock traded up $0.13 during trading on Wednesday, reaching $6.33. The company’s stock had a trading volume of 2,267,000 shares, compared to its average volume of 2,502,586. The company has a debt-to-equity ratio of 0.94, a current ratio of 7.88 and a quick ratio of 7.79. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -17.05 and a beta of 1.54. TherapeuticsMD Inc has a 1-year low of $4.34 and a 1-year high of $7.66.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Monday, July 30th. The company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03). The business had revenue of $3.80 million during the quarter, compared to analyst estimates of $4.23 million. TherapeuticsMD had a negative return on equity of 80.75% and a negative net margin of 582.86%. The firm’s revenue for the quarter was down 11.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.10) EPS. equities research analysts anticipate that TherapeuticsMD Inc will post -0.63 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Cetera Advisors LLC boosted its position in shares of TherapeuticsMD by 18.1% in the 1st quarter. Cetera Advisors LLC now owns 57,450 shares of the company’s stock worth $281,000 after purchasing an additional 8,800 shares in the last quarter. ING Groep NV lifted its position in TherapeuticsMD by 3.4% during the 1st quarter. ING Groep NV now owns 278,138 shares of the company’s stock worth $1,355,000 after acquiring an additional 9,176 shares during the period. Swiss National Bank lifted its position in TherapeuticsMD by 4.0% during the 1st quarter. Swiss National Bank now owns 301,400 shares of the company’s stock worth $1,468,000 after acquiring an additional 11,600 shares during the period. Iridian Asset Management LLC CT lifted its position in TherapeuticsMD by 20.3% during the 2nd quarter. Iridian Asset Management LLC CT now owns 68,841 shares of the company’s stock worth $430,000 after acquiring an additional 11,629 shares during the period. Finally, OppenheimerFunds Inc. lifted its position in TherapeuticsMD by 0.7% during the 1st quarter. OppenheimerFunds Inc. now owns 1,646,316 shares of the company’s stock worth $8,017,000 after acquiring an additional 12,236 shares during the period. 66.14% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have recently issued reports on TXMD. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Saturday, August 25th. ValuEngine downgraded TherapeuticsMD from a “buy” rating to a “hold” rating in a report on Saturday, July 28th. BidaskClub raised TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Friday, June 8th. Oppenheimer set a $12.00 price objective on TherapeuticsMD and gave the stock a “buy” rating in a research report on Tuesday, June 5th. Finally, Cantor Fitzgerald raised their price objective on TherapeuticsMD from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 14th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $15.33.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

See Also: NASDAQ Stock Market Explained

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply